The Immune Thrombocytopenia market is expected to expand significantly, driven by innovations in therapies designed to treat this blood disorder. With an anticipated market size projected to reach approximately 4.08 billion USD by 2035 and a compound annual growth rate (CAGR) of 1.3%, the landscape of ITP treatment is evolving rapidly. High rates of chronic immune thrombocytopenia (ITP) cases...